For patients undergoing CABG, the no-touch group showed a significantly lower vein graft occlusion rate compared with the conventional group, with an absolute risk difference of −3.2%. HealthDay News ...

Anti-VEGFR-2 was used in the original study to demonstrate successful repopulation of the graft with endothelial progenitor cells. As native saphenous veins, used as control here, do not express VEGFR ...

From the Department of Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio. Abstract—Aortocoronary saphenous vein graft disease, with its increasing clinical sequelae, presents an important and ...

Read the full abstract... Background: Peripheral arterial disease (PAD) is frequently treated by either an infrainguinal autologous (using the patient's own veins) or synthetic graft bypass. The rate ...

Please provide your email address to receive an email when new articles are posted on . Compared with aspirin alone, aspirin plus ticagrelor was associated with reduced risk for vein graft failure ...

Please provide your email address to receive an email when new articles are posted on . Use of an external saphenous vein graft support device did not improve intimal hyperplasia area in patients ...

Supporting saphenous vein grafts used in CABG with a novel external stent-like device did not decrease the degree of intimal hyperplasia seen at 1 year compared with unsupported grafts, but ...

A novel device called venous external support (VEST) may lead to increased longevity and durability of saphenous (leg) vein grafting during coronary artery bypass surgery, according to a new trial ...

Saphenous vein grafts (SVGs) remain the most frequently used conduits in coronary artery bypass graft surgery (CABG). Despite advances in surgical techniques and pharmacotherapy, SVG failure rates ...

Vein graft occlusion occurs frequently and is related to adverse outcomes after coronary artery bypass grafting (CABG). Technical factors during CABG are determinative for early graft patency. To ...